首页> Oncology research> Significance of CA125 Monitoring during Maintenance Treatment with Poly(ADP-Ribose) Polymerase Inhibitor in Ovarian Cancer after First-Line Chemotherapy: Multicenter, Observational Study.

Significance of CA125 Monitoring during Maintenance Treatment with Poly(ADP-Ribose) Polymerase Inhibitor in Ovarian Cancer after First-Line Chemotherapy: Multicenter, Observational Study.

导出 OA

翻译打印收藏纠错

第一作者： Szymon,Piątek

第一单位： Department of Gynecologic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, 02-781, Poland.

作者： Szymon,Piątek ^[1] ; Anna,Dańska-Bidzińska ^[2] ; Paweł,Derlatka ^[2] ; Bartosz,Szymanowski ^[3] ; Renata,Duchnowska ^[3] ; Aleksandra,Zielińska ^[4] ; Natalia,Sawicka ^[4] ; Aleksander,Gorzeń ^[5] ; Wojciech,Michalski ^[6] ; Mariusz,Bidziński ^[1]

作者单位： Department of Gynecologic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, 02-781, Poland. ^[1] Department of Obstetrics and Gynecology, Medical University of Warsaw, Warsaw, 02-091, Poland. ^[2] Department of Oncology, Military Institute of Medicine-National Research Institute, Warsaw, 04-141, Poland. ^[3] Department of Obstetrics, Gynecology and Gynecological Oncology, Medical University of Warsaw, Warsaw, 02-091, Poland. ^[4] Faculty of Medicine, Medical University of Warsaw, Warsaw, 02-091, Poland. ^[5] Department of Biomedical Statistics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, 02-781, Poland. ^[6]

关键词 Ovarian cancer cancer antigen 125 surveillance poly(ADP-ribose) polymerase inhibitor recurrence